In September, Auxilium Pharmaceuticals' CEO Adrian Adams shrugged off a $2.2 billion acquisition offer from Dublin-based Endo International, saying he'd rather do a reverse merger with Canada's QLT. Endo upped its offer to $2.6 billion in cash and stock--enough to seal the deal, the company announced today.
West Pharmaceutical Services and HealthPrize Technologies are taking gamification to the next level. The companies are teaming up on a new, interactive initiative that encourages patients to take their medication and rewards them when they do.
Just as a federal judge says it's time to close the books on the Chantix litigation that's been moving through her Alabama court, Pfizer is preparing for another kind of fight over the drug. The company has been building its case for the FDA to clear the black-box warning off the stop-smoking drug's label, but patient groups are now petitioning the agency to add more heft to that warning instead.
Swiss citizens may have recently voted for some of the world's tightest controls on executive pay. But did that keep the Roche and Novartis pharma chiefs from pocketing more than 13 million Swiss francs ($13.6 million) last year? Not according to a new study.
Merck's marketing team is adding another arrow to its quiver of community-oriented campaigns: a partnership with HBCU Connect, a niche media network targeting alumni and students of historically black colleges and universities.
Six months after announcing a series of deals aimed at refocusing its R&D efforts, Novartis is starting to provide some glimpses of what the new company will look like--and who will and will not be leading it.
A day after Sanofi informed U.S. officials it was looking into reports of employees paying bribes in the Middle East, GlaxosmithKline said it was doing the same in the United Arab Emirates.
Valeant CEO J. Michael Pearson has said he's confident Allergan shareholders will vote in support of his company's hostile bid come December. But it never hurts to have a little insurance.
What's a drugmaker hauled up for marketing violations to do? If you're Galderma, you declare yourself exempt from the rules.
Last month, the feds took issue with Bayer's marketing for its Phillips' Colon Health product, saying the company's claims lacked scientific backing. But the way the German pharma sees it, the legal standard the DOJ is holding it to is not only unfair, it's unprecedented.
Now, it's Sanofi digging into potential bribery in the Middle East. The French drugmaker told U.S. officials that it's eyeing allegations from an anonymous whistleblower about improper payments from 2007 to 2012.
Allergan's still okay with holding a special shareholder meeting on Dec. 18, a date it last month agreed on with wannabe acquirer Valeant. It just doesn't want its pursuer's partner, Bill Ackman, to have a say.
A debate has raged over the past couple of years over whether world governments are wasting money by stockpiling Roche's Tamiflu and GlaxoSmithKline's Relenza to help combat a potential flu epidemic. At issue is a tough question: Are the drugs effective enough to justify the estimated $2 billion spent to stockpile them?
Gilead Sciences' hepatitis C drug Sovaldi may be worth the sticker price. But it's too expensive for the U.K.'s health system to bear. That's the assessment in some National Health Service documents obtained by the Health Service Journal.
Teva and Mylan merge? Rumors are certainly swirling--and not for the first time, either. But while a potential deal might make financial sense, at least one analyst doesn't see it happening.
Ever since Pascal Soriot took the reins at AstraZeneca, he's been talking up Brilinta as a diamond in the rough. With some work, the clot-fighting drug really could become a blockbuster, the CEO figures. No, really.
Endo Health Solutions tried hard to ward off generic competitors for its big-selling pain med Opana ER. For instance, it petitioned the FDA to block competitors on safety grounds. According to a new lawsuit, Endo also paid off generics maker--and potential rival--Impax Laboratories.
On "60 Minutes," Dr. Peter Bach and Leonard Saltz deliver some sound bites that might get the general public talking--and politicians, too.
Back in April, Sanofi CEO Chris Viehbacher said he planned to sell off some of the company's mature products to make room for higher-value "bolt-on" acquisitions. Rumors about potential buyers immediately started flying. Analysts estimated the drugs could fetch $8 billion or more.
Lawyers in another Actos failure-to-warn trial claimed the company put profits ahead of patient safety, by keeping mum on study data that flagged links between the diabetes drug and cancer.